Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2025 06:12 ET | Source: Boehringer Ingelheim Limited

JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)

"Not intended for US or UK audiences."Ingelheim, GermanyApproval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the absolute change...
October 17, 2025 10:05 ET | Source: Boehringer Ingelheim Limited

Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC

Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were...
October 15, 2025 08:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio

Boehringer and AimedBio partner to develop novel antibody-drug conjugate therapy aiming to transform the treatment landscape for a broad range of cancers.
October 09, 2025 06:05 ET | Source: Boehringer Ingelheim Limited

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1Approval is based on results from two...
September 29, 2025 08:05 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim launches new direct-to-consumer platform to expand patient access to important treatments

Ridgefield, Connecticut, U.S. Boehringer Ingelheim today announced the launch of its new direct-to-consumer platform, “Boehringer Ingelheim Access.” The platform will offer a convenient way for...
September 29, 2025 02:05 ET | Source: Boehringer Ingelheim Limited

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without...
September 01, 2025 03:05 ET | Source: Boehringer Ingelheim Limited

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1...
August 18, 2025 08:05 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases

Boehringer and Palatin Technologies team up to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
August 08, 2025 15:25 ET | Source: Boehringer Ingelheim Limited

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK media. HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical...
August 07, 2025 10:05 ET | Source: Boehringer Ingelheim Limited

Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia

CT-155 showed a reduction in experiential negative symptoms as an adjunct to standard of care antipsychotic therapy from baseline to week 16, as measured by CAINS-MAP.CT-155 is an investigational...